We are live on ! Find out more
CC

Callan Capital Portfolio holdings

AUM $1.35B
1-Year Est. Return 8.35%
This Fund
S&P 500
This Quarter Est. Return
+4.78%
1 Year Est. Return
+8.35%
3 Year Est. Return
+20.11%
5 Year Est. Return
+98.58%
10 Year Est. Return
+95.87%
AUM
$477M
AUM Growth
+$6.42M
Cap. Flow
-$17.8M
Cap. Flow %
-3.74%
Top 10 Hldgs %
75.49%
Holding
73
New
5
Increased
26
Reduced
20
Closed
3

Sector Composition

Rank Sector Weight
1 Miscellaneous 97.04%
2 Healthcare 2.02%
3 Real Estate 0.38%
4 Consumer Staples 0.23%
5 Materials 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AAXJ icon
26
iShares MSCI All Country Asia ex Japan ETF
AAXJ
$3.88B
$2.22M 0.47%
35,232
-1,421
-4% -$94.7K
IYF icon
27
iShares US Financials ETF
IYF
$4.31B
$1.91M 0.4%
42,504
BIIB icon
28
Biogen
BIIB
$32.3B
$1.83M 0.38%
4,526
BDX icon
29
Becton Dickinson
BDX
$51.6B
$1.8M 0.38%
13,059
+10,059
+335% +$1.39M
IWB icon
30
iShares Russell 1000 ETF
IWB
$49.1B
$1.7M 0.36%
14,619
-1,965
-12% -$232K
EBND icon
31
State Street SPDR Bloomberg Emerging Markets Local Bond ETF
EBND
$2.29B
$1.57M 0.33%
58,141
CMBS icon
32
iShares CMBS ETF
CMBS
$472M
$1.56M 0.33%
30,419
+3
+0% +$155
XLB icon
33
State Street Materials Select Sector SPDR ETF
XLB
$8.81B
$1.54M 0.32%
63,824
+2,294
+4% +$57.7K
SJNK icon
34
State Street SPDR Bloomberg Short Term High Yield Bond ETF
SJNK
$4.8B
$1.54M 0.32%
53,246
+11
+0% +$321
RLY icon
35
State Street Multi-Asset Real Return ETF
RLY
$1.35B
$1.4M 0.29%
53,963
+27
+0.1% +$723
XLU icon
36
State Street Utilities Select Sector SPDR ETF
XLU
$21.9B
$1.3M 0.27%
62,700
+2,744
+5% +$60.1K
MLPX icon
37
Global X MLP & Energy Infrastructure ETF
MLPX
$3.63B
$1.27M 0.27%
23,609
BMR
38
DELISTED
BIOMED REALTY TRUST INC
BMR
$1.25M 0.26%
64,584
SGYP
39
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$1.25M 0.26%
150,100
-111,122
-43% -$539K
ZVO
40
DELISTED
Zovio Inc. Common Stock
ZVO
$1.12M 0.23%
116,724
+18,306
+19% +$174K
ARNA
41
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.08M 0.23%
23,200
-3,000
-11% -$130K
VV icon
42
Vanguard Morningstar Large-Cap ETF
VV
$54.3B
$955K 0.2%
10,072
+606
+6% +$58.7K
DBC icon
43
Invesco DB Commodity Index Tracking Fund
DBC
$1.82B
$936K 0.2%
52,021
AXJL
44
DELISTED
WisdomTree Asia-Pacific ex-Japan Fund
AXJL
$844K 0.18%
12,842
SQNM
45
DELISTED
SEQUENOM INC NEW
SQNM
$840K 0.18%
276,477
+10,000
+4% +$37.6K
MINT icon
46
PIMCO Enhanced Short Maturity Active Exchange-Traded Fund
MINT
$17.4B
$815K 0.17%
+8,054
New +$815K
ITCI
47
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$742K 0.16%
+23,232
New +$589K
NBIX icon
48
Neurocrine Biosciences
NBIX
$15.7B
$716K 0.15%
15,000
-5,000
-25% -$212K
MON
49
DELISTED
Monsanto Co
MON
$650K 0.14%
6,098
ARE icon
50
Alexandria Real Estate Equities
ARE
$8.87B
$569K 0.12%
6,509

Similar funds

Callan Capital's Q2 2015 Portfolio in Review

As of Q2 2015, Callan Capital held 73 positions worth $477M, up 1.4% from $470M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Callan Capital withdrew a net $17.8M in Q2 2015, closing 3 positions and reducing 20 holdings. Its most notable exit was Halozyme, an estimated $920K position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 97% of assets, down from 97% a quarter earlier, followed by Healthcare and Real Estate.

Against the trend, Callan Capital opened a new position in PIMCO Enhanced Short Maturity Active Exchange-Traded Fund worth $815K.

  • Callan Capital's largest Q2 2015 buy was PIMCO Enhanced Short Maturity Active Exchange-Traded Fund: 8,054 shares worth $815K.
  • Callan Capital added most to Becton Dickinson in Q2 2015, an estimated $1.39M increase.
  • Callan Capital's biggest Q2 2015 reduction was Vanguard FTSE Europe ETF, cutting an estimated $5.04M.
  • Callan Capital fully exited Halozyme in Q2 2015, selling an estimated $920K.
  • Callan Capital's ten largest holdings make up 75% of its $477M portfolio in Q2 2015.
  • Callan Capital opened 5 new positions and closed 3 in Q2 2015.
  • Callan Capital's portfolio value rose 1.4% quarter-over-quarter to $477M.

Based on Callan Capital's 13F filing for Q2 2015, filed 13 Aug 2015.